Cell & Gene Therapy
News
Control of Empty, Full and Partially Filled Capsids – BioPhorum establishing an Industry Position on this Critical Quality Attribute.
LONG READControl of empty, full and partially filled capsids BioPhorum establishing an industry position on this...
BioPhorum’s strategic framework shines a light on raw material management
Biopharmaceutical companies rely on a dependable supply of raw materials to ensure they can produce life-saving medicine...
Taking the BioPhorum value back into your organization – Pharmaron symposium
Ensuring that the BioPhorum value is shared and applied across the whole member organization is a topic that is importan...
Building on industry feedback to standardize plasmid release specifications
Plasmids release specifications are critical to the manufacture of many cell and gene therapy (CGT) products, but curren...
What do your key players need from IT systems in your CGT processes?
Manufacturing cell and gene therapies (CGTs) usually involve the coordinated efforts of staff in treatment centres, ship...
Orchestrating the supply of different cell and gene therapies
Cell and gene therapies (CGTs) and their patient-specific delivery of therapeutics are often seen as the future of medic...
Addressing the challenges of using RNA as a therapeutic or a gene-editing tool
RNA technologies, including mRNA therapeutics, have emerged as a promising drug modality due to their essential biologic...
Using a closure analysis method to reduce CGT contamination risks
Many cell therapy manufacturing processes use open unit manipulations. As a result, they are at risk of potential contam...
Bridging the worlds of IT and CGT through analogies
Cell and gene therapies (CGTs) have enormous potential to create personalized therapeutics for patients with diseases th...
BioPhorum’s Deliverables Report 2021 – all of our content at your fingertips
Where can you read about industry trends, progress against shared challenges, and best practice solutions...
A simplified way to register complex and innovative raw materials in Europe
The regulatory environment for registering innovative and complex raw materials differs by region and country. All natio...
Using a matrix approach to address challenges for potency assay development for in vivo and ex vivo gene therapies.
The gene therapy field is advancing rapidly and though there has been significant progress, there are yet relatively few...
Control of Empty, Full and Partially Filled Capsids – BioPhorum establishing an Industry Position on this Critical Quality Attribute.
LONG READControl of empty, full and partially filled capsids BioPhorum establishing an industry position on this critical quality attributePosition A consensus of BioPhorum member companies reject a proposed blanket minimum specification for percentage empty AAV capsids. Presently, it is premature...
BioPhorum’s strategic framework shines a light on raw material management
Biopharmaceutical companies rely on a dependable supply of raw materials to ensure they can produce life-saving medicine...
Taking the BioPhorum value back into your organization – Pharmaron symposium
Ensuring that the BioPhorum value is shared and applied across the whole member organization is a topic that is importan...
Building on industry feedback to standardize plasmid release specifications
Plasmids release specifications are critical to the manufacture of many cell and gene therapy (CGT) products, but curren...
What do your key players need from IT systems in your CGT processes?
Manufacturing cell and gene therapies (CGTs) usually involve the coordinated efforts of staff in treatment centres, ship...
Orchestrating the supply of different cell and gene therapies
Cell and gene therapies (CGTs) and their patient-specific delivery of therapeutics are often seen as the future of medic...
Addressing the challenges of using RNA as a therapeutic or a gene-editing tool
RNA technologies, including mRNA therapeutics, have emerged as a promising drug modality due to their essential biologic...
Using a closure analysis method to reduce CGT contamination risks
Many cell therapy manufacturing processes use open unit manipulations. As a result, they are at risk of potential contam...
Bridging the worlds of IT and CGT through analogies
Cell and gene therapies (CGTs) have enormous potential to create personalized therapeutics for patients with diseases th...
BioPhorum’s Deliverables Report 2021 – all of our content at your fingertips
Where can you read about industry trends, progress against shared challenges, and best practice solutions...
A simplified way to register complex and innovative raw materials in Europe
The regulatory environment for registering innovative and complex raw materials differs by region and country. All natio...
Using a matrix approach to address challenges for potency assay development for in vivo and ex vivo gene therapies.
The gene therapy field is advancing rapidly and though there has been significant progress, there are yet relatively few...
RNA: new CGT workstream to focus on this industry priority
When planning the 2021 BioPhorum Cell & Gene Therapy program, senior member representatives indicated that they want...